PT3683209T - Processo para preparar ácido [(5-(3-clorofenil)-3-hidroxipiridina-2-carbonil)-amino]acético a partir de 5-((3-clorofenil)-3-cloro-piridin-2-il)-nitrilo e processo para preparar derivados 5-((halogenofenil)-3-halogenopiridin-2-il)-nitrilo - Google Patents
Processo para preparar ácido [(5-(3-clorofenil)-3-hidroxipiridina-2-carbonil)-amino]acético a partir de 5-((3-clorofenil)-3-cloro-piridin-2-il)-nitrilo e processo para preparar derivados 5-((halogenofenil)-3-halogenopiridin-2-il)-nitriloInfo
- Publication number
- PT3683209T PT3683209T PT192144053T PT19214405T PT3683209T PT 3683209 T PT3683209 T PT 3683209T PT 192144053 T PT192144053 T PT 192144053T PT 19214405 T PT19214405 T PT 19214405T PT 3683209 T PT3683209 T PT 3683209T
- Authority
- PT
- Portugal
- Prior art keywords
- pyridin
- chlorophenyl
- preparing
- nitrile
- halophenyl
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 2
- JGRXMPYUTJLTKT-UHFFFAOYSA-N 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid Chemical compound C1=C(O)C(C(=O)NCC(=O)O)=NC=C1C1=CC=CC(Cl)=C1 JGRXMPYUTJLTKT-UHFFFAOYSA-N 0.000 title 1
- 125000005059 halophenyl group Chemical group 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/803—Processes of preparation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/82—Metals of the platinum group
- B01J2531/824—Palladium
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Enzymes And Modification Thereof (AREA)
- Curing Cements, Concrete, And Artificial Stone (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161493536P | 2011-06-06 | 2011-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3683209T true PT3683209T (pt) | 2021-12-15 |
Family
ID=47262177
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT192144053T PT3683209T (pt) | 2011-06-06 | 2012-06-05 | Processo para preparar ácido [(5-(3-clorofenil)-3-hidroxipiridina-2-carbonil)-amino]acético a partir de 5-((3-clorofenil)-3-cloro-piridin-2-il)-nitrilo e processo para preparar derivados 5-((halogenofenil)-3-halogenopiridin-2-il)-nitrilo |
| PT151898228T PT3000808T (pt) | 2011-06-06 | 2012-06-05 | Derivados de ácido 3-hidroxipiridino-2-il-carbonilamino]alcanóico 5-arilo ou 5-heteroarilo substituído, e seus sais bem como sua preparação a partir dos respectivos derivados de ácido 3-hidroxi-picolínico |
| PT127963742T PT2718265E (pt) | 2011-06-06 | 2012-06-05 | Processo para a preparação de ácidos, ésteres e amidas [(3-hidroxipiridino-2-carbonil)amino]alcanóicos |
| PT171913627T PT3290404T (pt) | 2011-06-06 | 2012-06-05 | Derivados de 5-((halogenofenil)-3-halogeno-piridin-2-il)-nitrilo como intermediários na preparação de derivados de ácido [(5-(halogenofenil)-3-hidroxipiridin-2-carbonil)-amino]alcanóico |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT151898228T PT3000808T (pt) | 2011-06-06 | 2012-06-05 | Derivados de ácido 3-hidroxipiridino-2-il-carbonilamino]alcanóico 5-arilo ou 5-heteroarilo substituído, e seus sais bem como sua preparação a partir dos respectivos derivados de ácido 3-hidroxi-picolínico |
| PT127963742T PT2718265E (pt) | 2011-06-06 | 2012-06-05 | Processo para a preparação de ácidos, ésteres e amidas [(3-hidroxipiridino-2-carbonil)amino]alcanóicos |
| PT171913627T PT3290404T (pt) | 2011-06-06 | 2012-06-05 | Derivados de 5-((halogenofenil)-3-halogeno-piridin-2-il)-nitrilo como intermediários na preparação de derivados de ácido [(5-(halogenofenil)-3-hidroxipiridin-2-carbonil)-amino]alcanóico |
Country Status (23)
| Country | Link |
|---|---|
| US (6) | US9145366B2 (esLanguage) |
| EP (5) | EP4026829A1 (esLanguage) |
| JP (6) | JP6290781B2 (esLanguage) |
| KR (5) | KR102171315B1 (esLanguage) |
| CN (1) | CN106518759B (esLanguage) |
| AU (4) | AU2012268426B2 (esLanguage) |
| CA (2) | CA2838194C (esLanguage) |
| CY (4) | CY1117177T1 (esLanguage) |
| DK (4) | DK3000808T3 (esLanguage) |
| ES (4) | ES2559850T3 (esLanguage) |
| HR (4) | HRP20151416T1 (esLanguage) |
| HU (4) | HUE048044T2 (esLanguage) |
| IL (1) | IL229775A (esLanguage) |
| LT (3) | LT3290404T (esLanguage) |
| MX (2) | MX347709B (esLanguage) |
| NO (1) | NO2686520T3 (esLanguage) |
| PL (4) | PL3683209T3 (esLanguage) |
| PT (4) | PT3683209T (esLanguage) |
| RS (3) | RS59902B1 (esLanguage) |
| RU (2) | RU2602083C2 (esLanguage) |
| SI (4) | SI3683209T1 (esLanguage) |
| SM (3) | SMT202000061T1 (esLanguage) |
| WO (1) | WO2012170377A1 (esLanguage) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009000286A (es) | 2006-06-26 | 2009-03-20 | Procter & Gamble | Inhibidores de prolil hidroxilasa y metodos de uso. |
| NO2686520T3 (esLanguage) | 2011-06-06 | 2018-03-17 | ||
| HUE066123T2 (hu) | 2013-06-13 | 2024-07-28 | Akebia Therapeutics Inc | Készítmények és módszerek anémia kezelésére |
| TW201946625A (zh) | 2013-11-15 | 2019-12-16 | 美商阿克比治療有限公司 | {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途 |
| CA2959688C (en) | 2014-09-02 | 2024-02-27 | Sunshine Lake Pharma Co., Ltd. | Quinolone compounds and their use to treat diseases related to hypoxia inducible factor and/or erythropoietin |
| CN107427503A (zh) | 2015-01-23 | 2017-12-01 | 阿克比治疗有限公司 | 2‑(5‑(3‑氟苯基)‑3‑羟基吡啶甲酰胺)乙酸的固体形式、其组合物及用途 |
| AU2016235534A1 (en) * | 2015-03-20 | 2017-10-12 | Akebia Therapeutics, Inc. | Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors |
| CN106146395B (zh) * | 2015-03-27 | 2019-01-01 | 沈阳三生制药有限责任公司 | 3-羟基吡啶化合物、其制备方法及其制药用途 |
| US11324734B2 (en) | 2015-04-01 | 2022-05-10 | Akebia Therapeutics, Inc. | Compositions and methods for treating anemia |
| EP3763703A3 (en) * | 2016-12-13 | 2021-03-03 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Novel crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid and processes for preparation thereof |
| IL269623B2 (en) * | 2017-03-29 | 2025-05-01 | Emerald Health Pharmaceuticals Inc | Cannabidiol derivatives as inhibitors of the hif prolyl hydroxylases activity |
| WO2019028150A1 (en) | 2017-08-01 | 2019-02-07 | Akebia Therapeutics, Inc. | COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES |
| JP7440989B2 (ja) | 2018-05-09 | 2024-02-29 | アケビア セラピューティクス インコーポレイテッド | ２－［５－（３－クロロフェニル）－３－ヒドロキシピリジン－２－カルボニル］アミノ］酢酸を調製するための方法 |
| WO2020075199A1 (en) | 2018-10-12 | 2020-04-16 | Mylan Laboratories Limited | Polymorphic forms of vadadustat |
| WO2020108941A1 (en) | 2018-11-28 | 2020-06-04 | Sandoz Ag | Multi-component crystals of an orally available hif prolyl hydroxylase inhibitor |
| JP7470106B2 (ja) * | 2019-04-26 | 2024-04-17 | 株式会社カネカ | Ｖａｄａｄｕｓｔａｔ中間体の製造方法 |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
| CN111087343B (zh) * | 2019-11-29 | 2022-02-18 | 万华化学集团股份有限公司 | 一种羟基吡啶配体及其制备方法和催化应用 |
| JP7594546B2 (ja) * | 2019-12-10 | 2024-12-04 | 田辺三菱製薬株式会社 | 含窒素ヘテロアリールカルボキサミド酢酸誘導体の製造方法 |
| WO2021149724A1 (ja) | 2020-01-24 | 2021-07-29 | Ａｐｓジャパン株式会社 | 光触媒ユニット及び該光触媒ユニットを備えたマスク |
| US20230286918A1 (en) | 2020-07-02 | 2023-09-14 | Akebia Therapeutics, Inc. | Manufacturing process for 3,5-dichloropicolinonitrile for synthesis of vadadustat |
| GB202011431D0 (en) * | 2020-07-23 | 2020-09-09 | Johnson Matthey Plc | Polymorphs of vadadustat and methods for preparing the polymorphs |
| EP4447963A1 (en) | 2021-12-17 | 2024-10-23 | Akebia Therapeutics Inc. | Selective phd1 inhibitor compounds, compositions, and methods of use |
| WO2024165507A1 (en) | 2023-02-06 | 2024-08-15 | Institut National de la Santé et de la Recherche Médicale | Use of hif-1α stabilizing agents for the treatment of type i interferonopathies |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3655679A (en) * | 1969-06-25 | 1972-04-11 | Merck & Co Inc | Certain aryl pyridine carboxylic acid derivatives |
| US3703582A (en) * | 1970-04-20 | 1972-11-21 | Merck & Co Inc | Aryl pyridine carboxylic acids in the treatment of inflammation |
| US3894920A (en) | 1971-12-21 | 1975-07-15 | Sagami Chem Res | Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives |
| US4016287A (en) | 1972-07-17 | 1977-04-05 | Boehringer Ingelheim Gmbh | Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof |
| TW219933B (esLanguage) | 1990-02-26 | 1994-02-01 | Lilly Co Eli | |
| US5405613A (en) | 1991-12-11 | 1995-04-11 | Creative Nutrition Canada Corp. | Vitamin/mineral composition |
| TW352384B (en) | 1992-03-24 | 1999-02-11 | Hoechst Ag | Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals |
| DE4219158A1 (de) | 1992-06-11 | 1993-12-16 | Thomae Gmbh Dr K | Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DK0650960T3 (da) * | 1993-11-02 | 1997-09-01 | Hoechst Ag | Substituerede heterocykliske carboxylsyreamid-estere, deres fremstilling og deres anvendelse som lægemidler. |
| ATE149486T1 (de) | 1993-11-02 | 1997-03-15 | Hoechst Ag | Substituierte heterocyclische carbonsäureamide, ihre herstellung und ihre verwendung als arzneimittel |
| TW406076B (en) | 1993-12-30 | 2000-09-21 | Hoechst Ag | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals |
| DE4410423A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE4410480A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US5789426A (en) | 1995-01-20 | 1998-08-04 | Cornell Research Foundation, Inc. | Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation |
| IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| JPH09221476A (ja) | 1995-12-15 | 1997-08-26 | Otsuka Pharmaceut Co Ltd | 医薬組成物 |
| CA2253282A1 (en) | 1996-04-30 | 1997-11-06 | Hoechst Aktiengesellschaft | 3-alkoxypyridine-2-carboxylic acid amide esters, their preparation and their use as drugs |
| DE19620041A1 (de) | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| DE19650215A1 (de) | 1996-12-04 | 1998-06-10 | Hoechst Ag | 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
| US6420427B1 (en) | 1997-10-09 | 2002-07-16 | Ono Pharmaceutical Co., Ltd. | Aminobutyric acid derivatives |
| DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| HUP0101482A3 (en) | 1998-03-23 | 2002-12-28 | Aventis Pharm Prod Inc | Piperidinyl and n-amidinopiperidinyl derivatives, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing the same |
| US6159379A (en) | 1999-05-04 | 2000-12-12 | Baker Hughes Incorporated | Organic ammonium salts for the removal of water soluble organics in produced water |
| JP2001048786A (ja) | 1999-08-05 | 2001-02-20 | Yamanouchi Pharmaceut Co Ltd | 三環式ヘテロアリール誘導体 |
| US6589758B1 (en) | 2000-05-19 | 2003-07-08 | Amgen Inc. | Crystal of a kinase-ligand complex and methods of use |
| US6849718B2 (en) | 2001-03-20 | 2005-02-01 | Dana Farber Cancer Institute, Inc. | Muteins of hypoxia inducible factor alpha and methods of use thereof |
| US6855510B2 (en) | 2001-03-20 | 2005-02-15 | Dana Farber Cancer Institute, Inc. | Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| EP1379630B1 (en) | 2001-03-21 | 2012-09-26 | Isis Innovation Limited | Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase |
| SE0101327D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | New crystalline forms |
| US6566088B1 (en) | 2001-10-04 | 2003-05-20 | Board Of Regents, The University Of Texas System | Prolyl-4-hydroxylases |
| GB0124941D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| CN102552263A (zh) | 2001-12-06 | 2012-07-11 | 法布罗根股份有限公司 | 提高内源性红细胞生成素(epo)的方法 |
| AU2003234624B8 (en) | 2002-05-17 | 2009-03-12 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| WO2004019868A2 (en) * | 2002-08-29 | 2004-03-11 | Merck & Co., Inc. | N-biarylmethyl aminocycloalkanecarboxamide derivatives |
| ES2337043T3 (es) | 2002-10-16 | 2010-04-20 | Isis Innovation Limited | Metodos de escrutinio empleando un modelo estructural de fih. |
| EP1567528A1 (en) | 2002-11-21 | 2005-08-31 | Eli Lilly And Company | Mixed lineage kinase modulators |
| US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| US7183287B2 (en) | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
| US20060251638A1 (en) | 2003-06-06 | 2006-11-09 | Volkmar Guenzler-Pukall | Cytoprotection through the use of hif hydroxylase inhibitors |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| EP1644336B1 (en) | 2003-06-06 | 2011-01-19 | Fibrogen, Inc. | Nitrogen-containing heteroaryl compounds and their use in increasing endogeneous erythropoietin |
| GB0314129D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| WO2005108370A1 (ja) | 2004-04-16 | 2005-11-17 | Ajinomoto Co., Inc. | ベンゼン化合物 |
| US20080113383A1 (en) | 2004-05-28 | 2008-05-15 | Fibro Gen, Inc. | Hif Prolyl Hydroxylase Activity Assay |
| WO2005115984A2 (en) | 2004-05-31 | 2005-12-08 | Tanabe Seiyaku Co., Ltd. | Large conductance calcium-activitated k channel opener |
| EP1771169A1 (en) | 2004-07-14 | 2007-04-11 | PTC Therapeutics, Inc. | Methods for treating hepatitis c |
| TW200616969A (en) | 2004-09-17 | 2006-06-01 | Tanabe Seiyaku Co | Imidazole compound |
| US20080213404A1 (en) | 2005-02-04 | 2008-09-04 | Johnson Randall S | Hif Modulating Compounds and Methods of Use Thereof |
| DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| AU2006254897A1 (en) | 2005-06-06 | 2006-12-14 | Fibrogen, Inc. | Improved treatment for anemia using a HIF-alpha stabilising agent |
| ATE470439T1 (de) | 2005-06-15 | 2010-06-15 | Fibrogen Inc | Verwendung von hif 1alfa modulatoren zur behandlung von krebs |
| US20070154482A1 (en) | 2005-09-12 | 2007-07-05 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
| WO2007038571A2 (en) | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| WO2007047194A2 (en) | 2005-10-11 | 2007-04-26 | Dana-Farber Cancer Institute, Inc. | Methods for treating mitf-related disorders |
| JP5202327B2 (ja) | 2005-12-09 | 2013-06-05 | アムジエン・インコーポレーテツド | プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用 |
| MX2008008608A (es) | 2006-01-09 | 2009-03-04 | Btg Int Ltd | Moduladores de factor i inducible por hipoxia y usos relacionados. |
| WO2007082899A1 (en) | 2006-01-17 | 2007-07-26 | Vib Vzw | Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration |
| JP4801451B2 (ja) | 2006-01-19 | 2011-10-26 | 株式会社日立ハイテクノロジーズ | 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法 |
| EP1979353A2 (en) | 2006-01-19 | 2008-10-15 | OSI Pharmaceuticals, Inc. | Fused heterobicyclic kinase inhibitors |
| ITMI20060179A1 (it) | 2006-02-02 | 2007-08-03 | Abiogen Pharma Spa | Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse |
| WO2007101204A1 (en) | 2006-02-27 | 2007-09-07 | Alcon Research, Ltd. | Method of treating glaucoma |
| US7588924B2 (en) | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
| PE20071020A1 (es) | 2006-03-07 | 2007-12-11 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa |
| WO2007136990A2 (en) | 2006-05-16 | 2007-11-29 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| TWI394747B (zh) | 2006-06-23 | 2013-05-01 | Smithkline Beecham Corp | 脯胺醯基羥化酶抑制劑 |
| MX2009000286A (es) | 2006-06-26 | 2009-03-20 | Procter & Gamble | Inhibidores de prolil hidroxilasa y metodos de uso. |
| CL2008000066A1 (es) | 2007-01-12 | 2008-08-01 | Smithkline Beecham Corp | Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem |
| CL2008000065A1 (es) | 2007-01-12 | 2008-09-22 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia. |
| CN101663037A (zh) | 2007-04-18 | 2010-03-03 | 默克公司 | 新的1,8-二氮杂萘化合物 |
| ES2446418T3 (es) | 2007-04-18 | 2014-03-07 | Amgen, Inc | Derivados de indanona que inhiben la prolil hidroxilasa |
| AU2008248234B2 (en) | 2007-05-04 | 2011-02-03 | Amgen Inc. | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
| JP5349462B2 (ja) | 2007-05-16 | 2013-11-20 | メルク・シャープ・アンド・ドーム・コーポレーション | スピロインダロン |
| CN101765596B (zh) | 2007-05-18 | 2015-04-29 | 拜耳知识产权有限责任公司 | 用于治疗过增生症状和与血管生成有关疾病的缺氧诱导因子(hif)抑制剂 |
| ES2462416T3 (es) | 2007-08-06 | 2014-05-22 | Senju Pharmaceutical Co., Ltd. | Producto farmacéutico que contiene un inhibidor de la expresión de HIF-1 alfa y HIF-2 alfa |
| TW200908984A (en) | 2007-08-07 | 2009-03-01 | Piramal Life Sciences Ltd | Pyridyl derivatives, their preparation and use |
| WO2009037570A2 (en) | 2007-08-10 | 2009-03-26 | Crystalgenomics, Inc. | Pyridine derivatives and methods of use thereof |
| WO2009035534A2 (en) | 2007-09-07 | 2009-03-19 | The Cleveland Clinic Foundation | Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) |
| WO2009039323A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039321A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009043093A1 (en) | 2007-10-04 | 2009-04-09 | Newsouth Innovations Pty Limited | Hif inhibition |
| WO2009049112A1 (en) | 2007-10-10 | 2009-04-16 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009067790A1 (en) | 2007-11-26 | 2009-06-04 | Uti Limited Partnership | STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION |
| JP2011505367A (ja) | 2007-11-30 | 2011-02-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラーゼ阻害剤 |
| JP2011508725A (ja) | 2007-11-30 | 2011-03-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラーゼ阻害剤 |
| US8269008B2 (en) | 2007-12-03 | 2012-09-18 | Fibrogen, Inc. | Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions |
| EP2240178A4 (en) | 2007-12-19 | 2011-10-26 | Glaxosmithkline Llc | PROLYLHYDROXYLASEHEMMER |
| WO2009086592A1 (en) | 2008-01-04 | 2009-07-16 | Garvan Institute Of Medical Research | Method of increasing metabolism |
| US8952160B2 (en) | 2008-01-11 | 2015-02-10 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity |
| CA2716706C (en) * | 2008-03-03 | 2014-02-18 | Irm Llc | Compounds and compositions as tlr activity modulators |
| US20090228298A1 (en) * | 2008-03-04 | 2009-09-10 | The General Electric Company | System and method of morphology feature analysis of physiological data |
| US8129376B2 (en) * | 2008-03-20 | 2012-03-06 | Sundaresan Kumar | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase |
| AR071997A1 (es) | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina |
| CN102099335A (zh) | 2008-07-23 | 2011-06-15 | 弗·哈夫曼-拉罗切有限公司 | 杂环抗病毒化合物 |
| WO2010029577A2 (en) | 2008-09-15 | 2010-03-18 | Ganga Raju Gokaraju | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers |
| AU2009314155B2 (en) | 2008-11-14 | 2015-10-08 | Fibrogen, Inc. | Thiochromene derivatives as HIF hydroxylase inhibitors |
| HRP20130846T1 (hr) * | 2009-03-31 | 2013-11-22 | Kissei Pharmaceutical Co., Ltd. | Derivati indolizina i njihova uporaba u medicinske svrhe |
| KR20140095105A (ko) | 2009-11-06 | 2014-07-31 | 에르피오 세러퓨틱스 인코포레이티드 | 대장염 치료용 조성물 및 방법 |
| RU2602498C2 (ru) | 2011-06-06 | 2016-11-20 | Акебиа Терапеутикс Инк. | Соединения и композиции для стабилизации индуцируемого гипоксией фактора-2 альфа как способ лечения рака |
| NO2686520T3 (esLanguage) * | 2011-06-06 | 2018-03-17 | ||
| WO2012174256A2 (en) | 2011-06-17 | 2012-12-20 | The Regents Of The University Of Michigan | Dna methylation profiles in cancer |
| JP6099644B2 (ja) | 2011-07-22 | 2017-03-22 | ベイジン ベータ ファーマシューティカルズ カンパニー， リミテッド | プロリルヒドロキシラーゼ阻害剤としての化合物の多形体、およびその使用 |
| WO2014168986A1 (en) | 2013-04-08 | 2014-10-16 | Brown Dennis M | Therapeutic benefit of suboptimally administered chemical compounds |
| HUE066123T2 (hu) | 2013-06-13 | 2024-07-28 | Akebia Therapeutics Inc | Készítmények és módszerek anémia kezelésére |
| WO2015023967A2 (en) | 2013-08-16 | 2015-02-19 | Ohio State Innovation Foundation | Compositions and methods for modulating dna methylation |
| TW201946625A (zh) | 2013-11-15 | 2019-12-16 | 美商阿克比治療有限公司 | {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途 |
| CA2937349A1 (en) | 2014-01-23 | 2015-07-30 | Akebia Therapeutics, Inc. | Compositions and methods for treating ocular diseases |
| CN107427503A (zh) | 2015-01-23 | 2017-12-01 | 阿克比治疗有限公司 | 2‑(5‑(3‑氟苯基)‑3‑羟基吡啶甲酰胺)乙酸的固体形式、其组合物及用途 |
| AU2016235534A1 (en) | 2015-03-20 | 2017-10-12 | Akebia Therapeutics, Inc. | Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors |
| US11324734B2 (en) | 2015-04-01 | 2022-05-10 | Akebia Therapeutics, Inc. | Compositions and methods for treating anemia |
| JP7440989B2 (ja) | 2018-05-09 | 2024-02-29 | アケビア セラピューティクス インコーポレイテッド | ２－［５－（３－クロロフェニル）－３－ヒドロキシピリジン－２－カルボニル］アミノ］酢酸を調製するための方法 |
-
2012
- 2012-03-05 NO NO12759983A patent/NO2686520T3/no unknown
- 2012-06-05 SM SM20200061T patent/SMT202000061T1/it unknown
- 2012-06-05 LT LTEP17191362.7T patent/LT3290404T/lt unknown
- 2012-06-05 EP EP21206374.7A patent/EP4026829A1/en active Pending
- 2012-06-05 KR KR1020197037296A patent/KR102171315B1/ko active Active
- 2012-06-05 SI SI201231969T patent/SI3683209T1/sl unknown
- 2012-06-05 DK DK15189822.8T patent/DK3000808T3/da active
- 2012-06-05 EP EP15189822.8A patent/EP3000808B1/en active Active
- 2012-06-05 MX MX2015016579A patent/MX347709B/es unknown
- 2012-06-05 PT PT192144053T patent/PT3683209T/pt unknown
- 2012-06-05 EP EP12796374.2A patent/EP2718265B1/en active Active
- 2012-06-05 PT PT151898228T patent/PT3000808T/pt unknown
- 2012-06-05 HU HUE17191362A patent/HUE048044T2/hu unknown
- 2012-06-05 ES ES12796374.2T patent/ES2559850T3/es active Active
- 2012-06-05 PL PL19214405T patent/PL3683209T3/pl unknown
- 2012-06-05 SI SI201231114T patent/SI3000808T1/en unknown
- 2012-06-05 KR KR1020197007630A patent/KR102059366B1/ko active Active
- 2012-06-05 KR KR1020197007633A patent/KR102032864B1/ko active Active
- 2012-06-05 RS RS20200130A patent/RS59902B1/sr unknown
- 2012-06-05 ES ES15189822.8T patent/ES2647602T3/es active Active
- 2012-06-05 RU RU2013158640/04A patent/RU2602083C2/ru active
- 2012-06-05 HR HRP20151416T patent/HRP20151416T1/hr unknown
- 2012-06-05 CA CA2838194A patent/CA2838194C/en active Active
- 2012-06-05 RS RS20160013A patent/RS54517B1/sr unknown
- 2012-06-05 KR KR1020147000297A patent/KR102000485B1/ko active Active
- 2012-06-05 EP EP17191362.7A patent/EP3290404B1/en active Active
- 2012-06-05 DK DK17191362.7T patent/DK3290404T3/da active
- 2012-06-05 SI SI201230432T patent/SI2718265T1/sl unknown
- 2012-06-05 PL PL17191362T patent/PL3290404T3/pl unknown
- 2012-06-05 MX MX2013014228A patent/MX337216B/es active IP Right Grant
- 2012-06-05 DK DK12796374.2T patent/DK2718265T3/en active
- 2012-06-05 LT LTEP19214405.3T patent/LT3683209T/lt unknown
- 2012-06-05 HU HUE19214405A patent/HUE057571T2/hu unknown
- 2012-06-05 HR HRP20211916TT patent/HRP20211916T1/hr unknown
- 2012-06-05 ES ES19214405T patent/ES2900572T3/es active Active
- 2012-06-05 ES ES17191362T patent/ES2771232T3/es active Active
- 2012-06-05 PL PL15189822T patent/PL3000808T3/pl unknown
- 2012-06-05 DK DK19214405.3T patent/DK3683209T3/da active
- 2012-06-05 SI SI201231729T patent/SI3290404T1/sl unknown
- 2012-06-05 PL PL12796374T patent/PL2718265T3/pl unknown
- 2012-06-05 RU RU2016139352A patent/RU2764667C2/ru active
- 2012-06-05 CA CA3135440A patent/CA3135440A1/en active Pending
- 2012-06-05 PT PT127963742T patent/PT2718265E/pt unknown
- 2012-06-05 US US13/488,554 patent/US9145366B2/en active Active
- 2012-06-05 RS RS20171181A patent/RS56580B1/sr unknown
- 2012-06-05 PT PT171913627T patent/PT3290404T/pt unknown
- 2012-06-05 CN CN201610967348.7A patent/CN106518759B/zh active Active
- 2012-06-05 LT LTEP15189822.8T patent/LT3000808T/lt unknown
- 2012-06-05 HU HUE12796374A patent/HUE026096T2/en unknown
- 2012-06-05 WO PCT/US2012/040833 patent/WO2012170377A1/en not_active Ceased
- 2012-06-05 AU AU2012268426A patent/AU2012268426B2/en active Active
- 2012-06-05 EP EP19214405.3A patent/EP3683209B1/en active Active
- 2012-06-05 SM SM20170534T patent/SMT201700534T1/it unknown
- 2012-06-05 KR KR1020207029586A patent/KR102293016B1/ko active Active
- 2012-06-05 JP JP2014514536A patent/JP6290781B2/ja active Active
- 2012-06-05 HU HUE15189822A patent/HUE034975T2/en unknown
-
2013
- 2013-12-03 IL IL229775A patent/IL229775A/en active IP Right Grant
-
2015
- 2015-08-24 US US14/833,222 patent/US9776969B2/en active Active
-
2016
- 2016-01-14 CY CY20161100037T patent/CY1117177T1/el unknown
- 2016-01-15 SM SM201600013T patent/SMT201600013B/it unknown
-
2017
- 2017-04-12 AU AU2017202414A patent/AU2017202414B2/en active Active
- 2017-08-31 US US15/692,255 patent/US10246416B2/en active Active
- 2017-11-13 HR HRP20171740TT patent/HRP20171740T1/hr unknown
- 2017-11-15 CY CY20171101202T patent/CY1119605T1/el unknown
-
2018
- 2018-02-08 JP JP2018020595A patent/JP6510094B2/ja active Active
- 2018-10-15 AU AU2018250355A patent/AU2018250355B2/en active Active
-
2019
- 2019-03-13 US US16/352,705 patent/US10738010B2/en active Active
- 2019-04-03 JP JP2019070979A patent/JP6816195B2/ja active Active
-
2020
- 2020-02-03 CY CY20201100087T patent/CY1122639T1/el unknown
- 2020-02-06 HR HRP20200197TT patent/HRP20200197T1/hr unknown
- 2020-07-06 US US16/921,273 patent/US11267785B2/en active Active
- 2020-07-07 AU AU2020204528A patent/AU2020204528B2/en active Active
- 2020-12-23 JP JP2020213442A patent/JP7039682B2/ja active Active
-
2021
- 2021-12-08 CY CY20211101079T patent/CY1124874T1/el unknown
-
2022
- 2022-01-31 US US17/589,118 patent/US20230002323A1/en active Pending
- 2022-03-09 JP JP2022035813A patent/JP7284309B2/ja active Active
-
2023
- 2023-05-18 JP JP2023081959A patent/JP7685552B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE057571T2 (hu) | Eljárás [(5-(3-klór-fenil)-3-hidroxi-piridin-2-karbonil)-amino]-ecetsav elõállítására 5-((3-klór-fenil)-3-klór-piridin-2-il)-nitrilbõl kiindulva, és eljárás 5-(halogén-fenil)-3-halogén-piridin-2-il)-nitril-származékok elõállítására | |
| ZA201005350B (en) | Process for preparing 2-amino-5-cyanobenzoic acid derivatives | |
| PL2678035T3 (pl) | Pochodne fenalen-1-onu, sposób ich wytwarzania i zastosowanie | |
| IL206390A0 (en) | Process for preparing 2-amino-5-cyanobenzoic acid derivatives | |
| IL225352A0 (en) | Process for the preparation of cdk-pan inhibitors according to formula (i) and intermediates in the preparation | |
| IL222290A0 (en) | Process for preparing aminobenzofuran derivatives | |
| IL222191A0 (en) | Process for preparing sulfonamido-benzofuran derivatives | |
| IL220211A0 (en) | Process for the preparation of 1-alkyl-/1-aryl-5-pyrazolecarboxylic acid derivatives | |
| IL231141A (en) | Process for making 2 - (6-fluoro-1 h-indole-3-yl) - n, n - dimethylmethanamine | |
| IL201670A0 (en) | Process for preparing 2-amino-5-cyanobenzoic acid derivatives | |
| EP2763998A4 (en) | TRI-HETEROCYCLIC DERIVATIVES, MANUFACTURING METHOD AND USES THEREOF | |
| ZA201106628B (en) | Process for the preparation of propionic acid derivatives | |
| IL227220A (en) | A process for preparing a history of 3-alkylsulfinylbenzoyl | |
| IL227544B (en) | (r)- Leoplomide, a method for its preparation and its medical uses | |
| IL248698B (en) | History of 1-h-pyrrolidine-4,2-dione and processes for their preparation | |
| IL225680A0 (en) | Process for preparing 3-(6-amino-pyridin-3-yl)2-acrylic acid derivatives | |
| PL2771328T3 (pl) | Sposób otrzymywania 1,2-benzizotiazolin-3-onu | |
| EP2604591A4 (en) | PROCESS FOR THE PREPARATION OF AMINOADAMANTYL CARBAMATE DERIVATIVES | |
| PL2734492T3 (pl) | Sposób wytwarzania 1,1,1-trifluoropropanu | |
| PL2791201T3 (pl) | Sposób wytwarzania określonych funkcjonalnych oligomerów kwasu mlekowego | |
| ZA201205062B (en) | Process for the preparation of propionic acid derivatives | |
| IL226097A0 (en) | A process for the production of derivatives of 4-carbonyloxyquinoline | |
| SG11201402888UA (en) | Process for the manufacture of acetic acid | |
| SG11201402858PA (en) | Process for the manufacture of acetic acid | |
| SMT201700432T1 (it) | Procedimento per la preparazione di acido [4,6-bis-dimetilammino-2-[4-(4-trifluorometilbenzoil-ammino)benzil)pirimidin-5-il]acetico |